A Phase III, Randomized, Double-blind, Active-controlled 12 week Study Evaluating the Efficacy and Safety of KRP-AB1102F DPI Compared with KRP-AB1102 DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Aclidinium bromide/formoterol (Primary) ; Aclidinium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 07 Jun 2016 New trial record